CCL5 and breast carcinoma: The immunosuppressive state of the breast cancer TME makes it difficult to treat with immunotherapy, but the chimeric oncolytic adenovirus armed with the chemokine regulated after activation, expressed and secreted by normal T cells (RANTES)/CC chemokine ligand 5 (CCL5) appears to be a promising drug candidate for the treatment of breast cancer (Ang et al., 2022).